간행물

생화학분자생물학회입니다.


BMB Reports

AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism

  • 작성자

    Soojin Jang
  • 작성일자

    2023-07-20
  • 조회수

    1442
Name: Soojin Jang ( soojin.jang@ip-korea.org )
2014-presentTeam leader, Antibacterial Resistance Laboratory, Institut Pasteur Korea
2013-2014Postdoctoral research fellow, Antibacterial Drug Discovery program, Institut Pasteur Korea
2010-2013Postdoctoral research fellow, Washington University in St. Louis School of Medicine
2003-2010Ph.D., Department of Microbiology, Univ. of Illinois at Chicago, USA

AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism

Antibiotic resistance (AR) is a silent pandemic that kills millions around world. Although development of new therapeutic agents against antibiotic resistance is in urgent demand, there has been a great challenge especially for Gram negative bacteria that have inherent drug-resistance mediated by impermeable outer membranes and multidrug efflux pumps that actively extrude various drugs from the bacteria. For the last two decades, multidrug efflux pumps including AcrAB-TolC, the most clinically important efflux pump in Gram negative bacteria, have drawn great attention as a strategic target for re-sensitizing bacteria to the existing antibiotics. This article aims to provide a concise overview of AcrAB-TolC operation mechanism reviewing its substrate specificity and recent development of AcrAB-TolC inhibitors. .


BMB Rep. 2023 Jun;56(6):326-334. doi: 10.5483/BMBRep.2023-0070.
https://pubmed.ncbi.nlm.nih.gov/37254571/